The list of medical technologies approved for innovation funding (NUB) in Germany in 2019

On January 29, 2019, the Institute for the Hospital Remuneration System (InEK) has published the List of the requests for innovation funding (NUB), submitted by the hospitals until October 31, 2018. Out of 709 requests, 180 (25%) received the positive status 1, which means that the evaluated procedure or medical device meets the NUB criteria and allows the hospitals to negotiate with the sickness funds for the innovation funding for these technologies.

The full list of 69 technologies, which obtained the status 1, is provided below:

1. Insertion of coated (covered) stents with bioactive surface for peripheral vessels;
2. Implantation of an intracardiac pulse generator;
3. Covered endoprosthesis with bioactive surface for dialysis shunt revision;
4. Ascites treatment by means of a fully implantable pump;
5. External stabilization device for anastomosis of an AV shunt within/as a part of the shunt surgery;
6. Endovascular implantation of an internal AV shunt by means of magnetically guided high-frequency energy;
7. Hemodynamically effective implant for the endovascular treatment of intracranial aneurysms and brain-supplying neck vessels;
8. Intra-aneurysmal hemodynamically effective implant for endovascular treatment of intracranial aneurysms;
9. Ultra-soft, removable micro-coils for the therapy of intracranial vascular malformations and aneurysms;
10. Gastric pacemaker implantation;
11. Wire mesh for flow reduction in the coronary sinus;
12. Endovascular implantation of an extracorporeal centrifugal pump for circulatory system support;
13. Endovascular mitral valve annuloplasty with annuloplasty tape;
14. Selective intravascular radionuclide therapy (SIRT) with holmium 166-labeled microspheres for radioembolization;
15. Endo-barrier for the treatment of obese type 2 diabetics;
16. Focal photodynamic therapy with Padeliporfin for the treatment of localized prostate cancer;
17. Lung volume reduction by means of bronchoscopic application of polymer foam;
18. Transapical mitral valve reconstruction by implantation of neochordae (PTFE);
19. Transcatheter implantation of an interatrial shunt device for the treatment of heart failure;
20. Transmission of virus-specific donor immune cells after allogeneic stem cell transplantation;
21. Temporomandibular joint replacement (total replacement);
22. Hypoglossal nerve stimulation system for the treatment of obstructive sleep apnea syndrome (OSAS);
23. Minimally invasive LV-reconstruction with a myocardial anchoring system;
24. Therapy of scoliosis by means of magnetically controlled rods;
25. Catheter-based implant for the treatment of left ventricular cardiac motility disorders;
26. Intra-aortal balloon occlusion with extracorporeal circulation;
27. Extracorporeal neurostimulation system for the peripheral nervous system;
28. Intra-aortic catheter with paracorporeal membrane pump for circulatory support of the left ventricle;
29. Cardiac resynchronization therapy with wireless left ventricular endocardial pacing;
30. Implantation of growing heart valves;
31. Therapy of scoliosis by means of a growing screw-rod-system;
32. Endo-Exo-Prostheses;
33. Implant for direct acoustic stimulation of the cochlea (DACI);
34. Insertion of coated (covered) stents with bioactive surface for peripheral and other vessels;
35. Insertion of coated (covered) stents with bioactive surface for intraabdominal, cranial or peripheral vessels;
36. Apicoaortal valve-carrying conduit;
37. Intracavitary radiotherapy with Iodine-125;
38. Fetoscopic drainage therapy;
39. Insertion of coated (covered) stents with bioactive surface for visceral and supra-aortal vessels;
40. Epiretinal retinal prosthesis;
41. Spine growth modulation technique;
42. Acoustic neurinoma operation with simultaneous cochlear implantation;
43. Endovascular mitral valve annuloplasty with seam anchoring;
44. Pulmonary arterial banding, telemetrically adjustable;
45. Radioimmunotherapy with anti-CD19, anti-CD45 and anti-CD66 antibodies;
46. Fetoscopic tracheal balloon lock in case of diaphragmatic hernia and premature tuberosity;
47. Subretinal active implant;
48. Closure of umbilical cord and intrafetal vessels by percutaneous ultrasound-controlled radiofrequency ablation or fetoscopic laser ablation;
49. Auditory brainstem implant;
50. Fetoscopic opening of narrowed semilunar valves and the foramen ovale;
51. Fetoscopic therapy of fetal supraventricular tachycardia and laryngeal or trachea occlusion;
52. Lutetium-177- or Yttrium-90-pentixafor therapy;
53. Keratoprosthesis, biologically coated;
54. Radioligand therapy with Actinium-225-PSMA-ligands;
55. Radionuclide therapy with Lutetium-177-bisphosphonate in bone metastases of the prostate carcinoma;
56. Uterine shield closure after fetoscopic interventions;
57. Allogenic hepatocytes transplantation;
58. Artificial larynx after total laryngectomy;
59. Expandable endoprosthesis;
60. Auditory midbrain implant;
61. Radionuclide therapy with Iodine-131-azetidinylamide in metastatic adrenal carcinoma;
62. Uterus transplantation;
63. Autologous matrix-induced hepatocytes transplantation;
64. Treatment of fatal epidermolysis bullosa junctionalis (Herlitz type) by transplantation of haploidentical bone marrow and skin of the same donor;
65. Treatment of the bladder/prostate/rectum/perineal region rhabdomyosarcoma with organ-preserving surgery and interstitial HDR brachytherapy in children;
66. Combined renal and stem cell transplantation (living donation);
67. Continuous amnion infusion by subcutaneous implanted port system;
68. Radionuclide therapy with Iodine-131-metomidate;
69. Complete face transplantation.

Two new technologies (transcatheter implantation of an interatrial shunt device for the treatment of heart failure and radioligand therapy with Actinium-225-PSMA-ligands) received status 1 in comparison with the list presented in 2018.

Furthermore, four procedures (percutaneous mitral valve anulorrhaphy with clasp, transapical implantation of an extracorporeal centrifugal pump for circulatory system support, fetoscopic patch closure at spina bifida aperta and radionuclide therapy with lutetium 177-labeled prostate-specific membrane antigen (PSMA) in prostate cancer) with status 1 in 2018, received status 2 in 2019.

The full details in German can be found here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.